Aurora Cannabis Inc.

Aurora Cannabis Inc. is a Canadian licensed cannabis producer headquartered in Edmonton, Alberta, Canada. The company's core business involves the cultivation, production, and global distribution of cannabis and cannabis-derivative products for both medical and consumer markets. With a mission to "Open the World to Cannabis," Aurora is dedicated to improving lives through its science-backed approach and extensive product portfolio.

Aurora offers a diverse range of products, including pharmaceutical-grade cannabis, dried flower, oils, concentrates, edibles, capsules, and vaporizers. Its adult-use brands feature names like Drift, San Rafael '71, Daily Special, Whistler, Being, Greybeard, and Tasty's, while its medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co., Pedanios, Bidiol, IndiMed, and CraftPlant. The company also holds a controlling interest in Bevo Farms Ltd., a significant supplier of propagated agricultural plants in North America, diversifying its market segments.

As of early 2026, Aurora Cannabis maintains its position as a leading Canadian licensed producer by medical cannabis revenue and ranks among the top three global medical cannabis players. The company recently reported strong Q3 FY2026 results, driven by record global medical cannabis revenue growth and positive free cash flow. In April 2026, Aurora acquired Safari Flower Co. for $26.5 million, enhancing its EU GMP-certified cultivation and manufacturing capacity to support its expanding international medical markets, particularly in Europe and Australia. Miguel Martin serves as the Chief Executive Officer, having been appointed in September 2020.

Latest updates

Aurora Expands Medical Cannabis Portfolio Across Key International Markets

Event summary

  • Aurora Cannabis launched new medical cannabis products across Canada, Europe (Germany, Poland), and Australia.
  • New product offerings include dried flower, pre-rolls, and pastilles, with THC percentages ranging from 21% to 29% and CBD levels generally below 1.0%.
  • The launches are intended to meet patient and prescriber demand and align with Aurora’s medical-first strategy, utilizing GMP-certified manufacturing.
  • The product rollouts are expected to be completed between now and June 2026.

The big picture

Aurora’s product launches signal a continued push for international medical cannabis market share, leveraging its GMP-certified manufacturing network. While the company emphasizes a medical-first approach, the product portfolio’s focus on higher THC content suggests a potential broadening of its target consumer base. The success of these launches will depend on navigating varying regulatory landscapes and maintaining a competitive edge in increasingly crowded markets.

What we're watching

Regulatory Scrutiny
Increased product variety and international expansion may draw greater scrutiny from regulatory bodies in each market, potentially impacting future approvals and operational costs.
Market Saturation
The expansion of product offerings, while responding to demand, could lead to increased competition and potential market saturation, requiring Aurora to differentiate further.
Cannabinoid Ratios
The prevalence of high-THC, low-CBD products suggests a focus on recreational-adjacent use; the long-term sustainability of this strategy in medically-focused markets warrants observation.

Aurora Cannabis Acquires Safari Flower to Bolster EU GMP Capacity

Event summary

  • Aurora Cannabis acquired Safari Flower Company for a total consideration of $26.5 million.
  • The acquisition includes a $2 million contingent cash payment based on performance conditions.
  • Safari Flower Company operates a 59,000 square foot EU GMP certified cultivation and manufacturing facility in Ontario, Canada.
  • Aurora intends to integrate the facility to expand its EU GMP flower supply for key international markets.

The big picture

Aurora’s acquisition of Safari Flower represents a strategic move to secure greater control over its EU GMP supply chain and capitalize on the expanding international medical cannabis market. The $26.5 million deal, while relatively modest in the context of larger industry transactions, underscores the ongoing consolidation within the cannabis sector as companies prioritize profitability and regulatory compliance. This acquisition signals a focus on expanding into high-margin, regulated markets, a shift from earlier growth-at-all-costs strategies.

What we're watching

Integration Risk
The success of the acquisition hinges on Aurora’s ability to effectively integrate Safari Flower’s facility and operations into its existing network, realizing the projected synergies and efficiencies.
Regulatory Landscape
Changes in EU GMP regulations or import/export policies could significantly impact the profitability and scalability of Aurora’s international operations.
Market Dynamics
The continued growth of the high-margin international medical cannabis markets, particularly in Germany, Australia, and the UK, will be crucial for Aurora to achieve the anticipated Adjusted EBITDA contributions.

Aurora Maintains Gender Diversity Recognition Amidst Shifting Cannabis Landscape

Event summary

  • Aurora Cannabis has been recognized for the second consecutive year on The Globe and Mail’s ‘Women Lead Here’ list.
  • The list acknowledges companies demonstrating strong executive-level gender diversity, with Aurora reporting 50% female executive leadership.
  • The recognition is attributed to Aurora's focus on developing a diverse pipeline of female talent and fostering an inclusive workplace culture.
  • Lori Schick, Executive Vice President, Human Resources, highlighted the company’s commitment to respect, accountability, and trust in leadership.

The big picture

While the recognition highlights Aurora’s efforts toward inclusive leadership, the broader cannabis industry faces ongoing challenges including regulatory uncertainty and fluctuating consumer demand. Maintaining a diverse leadership team can be a competitive advantage, but its impact on profitability remains to be seen as Aurora navigates a maturing market and seeks to maintain its position as a global medical cannabis leader.

What we're watching

Sustainability
The long-term impact of these diversity initiatives on Aurora’s financial performance and brand reputation warrants monitoring, particularly as investor scrutiny of ESG factors intensifies.
Leadership Retention
Whether Aurora can retain its female executive leadership team, and continue to attract diverse talent, will be crucial for sustaining this recognition and driving future growth.
Methodology
The Globe and Mail's methodology for assessing gender diversity is proprietary; understanding how it evolves and its weighting relative to other business metrics will be important for benchmarking Aurora’s progress.

Aurora Cannabis CFO to Address Investor Concerns at TD Cowen Conference

Event summary

  • Aurora Cannabis CFO Simona King will participate in TD Cowen’s Annual Health Care Conference on March 2, 2026.
  • The fireside chat, hosted by TD Cowen’s Derek Lessard, will focus on Aurora’s international leadership, manufacturing advancements, and market trends.
  • Aurora has completed its acquisition of Bevo Agtech Inc., details of which were announced on February 4, 2026.
  • The webcast will be available for replay for approximately 90 days.

The big picture

Aurora’s participation in the TD Cowen conference signals an effort to reassure investors amidst ongoing volatility in the cannabis sector. The completed Bevo acquisition suggests a continued focus on strategic growth, but the conference presentation will be critical in demonstrating a clear path to sustainable profitability and market leadership. The discussion around manufacturing excellence is particularly important given the need to differentiate through operational efficiency in a competitive landscape.

What we're watching

Financial Transparency
The discussion around Aurora’s international leadership will likely be scrutinized given past challenges in profitability across various markets; investors will be looking for concrete plans to improve margins.
Acquisition Integration
The success of the Bevo Agtech acquisition will be a key indicator of Aurora’s ability to execute on strategic M&A, and whether it can deliver the anticipated synergies.
Regulatory Landscape
The conference will likely highlight the ongoing shifts in global cannabis regulations, and how Aurora intends to navigate potential headwinds and capitalize on emerging opportunities.

Aurora Cannabis Rings Nasdaq Bell, Signals Medical Cannabis Focus

Event summary

  • Aurora Cannabis will ring the Nasdaq closing bell on February 18, 2026, in New York City.
  • CEO Miguel Martin and a Board representative will lead the ceremony.
  • The event is intended to highlight Aurora’s shift towards a medical-first, globally focused cannabis strategy.
  • Aurora serves markets in Canada, Europe, Australia, and New Zealand.

The big picture

Aurora's public display of commitment to its medical cannabis strategy signals a potential shift away from broader consumer markets, reflecting a move towards higher-margin, regulated segments. This event comes after a period of restructuring and strategic realignment within the company, as it seeks to solidify its position as a global leader in the medical cannabis space. The timing also suggests an effort to bolster investor confidence amidst ongoing volatility in the cannabis sector.

What we're watching

Market Acceptance
The success of Aurora’s medical-first strategy hinges on continued acceptance and expansion of medical cannabis programs in key international markets, which faces regulatory and cultural hurdles.
Financial Performance
Whether Aurora can sustain the high-margin profile it attributes to its medical business will be critical, given the competitive landscape and potential for pricing pressure.
Regulatory Risk
Changes in regulations surrounding cannabis, particularly in international markets, could significantly impact Aurora’s ability to expand and maintain its global footprint.

Aurora Expands Medical Cannabis Portfolio in Australia, New Zealand

Event summary

  • Aurora Cannabis is expanding its medical cannabis portfolio in Australia and New Zealand.
  • New Zealand launches include THC flower products (Big Wave™, Night Ride™, Half Moon™) and resin cartridges.
  • Australia will debut four new resin cartridges (Chemango™ Kush, Cosmic Cream™, Lunar Express™, Soul Train Haze™).
  • Stanley Sack, Interim Managing Director of MedReleaf Australia, highlighted the company’s commitment to the region.
  • Products are manufactured at Aurora’s EU-GMP and TGA-GMP certified facilities in Canada.

The big picture

Aurora’s expansion into Australia and New Zealand underscores the company’s continued focus on international medical cannabis markets, which represent a key growth area given the limitations of the Canadian market. While Australia is already a significant market, the move into New Zealand signals an ambition to capture a broader regional footprint. The reliance on Canadian manufacturing facilities for these products introduces logistical and regulatory complexities that could impact supply chain resilience and cost structure.

What we're watching

Regulatory Landscape
The evolving regulatory environment in Australia and New Zealand will dictate the pace of adoption and profitability for Aurora’s expanded product offerings, particularly concerning import/export regulations and local manufacturing approvals.
Competitive Response
Competitors in the Australian and New Zealand medical cannabis markets will likely respond to Aurora’s expansion with their own product launches and marketing initiatives, potentially intensifying price competition and eroding margins.
Patient Adoption
The rate at which Australian and New Zealand prescribers integrate these new products into patient care plans will determine the success of Aurora’s expansion, requiring ongoing education and relationship building with healthcare professionals.

Aurora Cannabis Expands Medical Portfolio in Australia, New Zealand

Event summary

  • Aurora Cannabis is expanding its medical cannabis portfolio in Australia and New Zealand.
  • New product launches include THC flower (Big Wave™, Night Ride™, Half Moon™) in New Zealand (Q1 FY27) and resin cartridges (Chemango™ Kush, Cosmic Cream™, Lunar Express™, Soul Train Haze™) in Australia.
  • Stanley Sack, Interim Managing Director of MedReleaf Australia, emphasized the commitment to meeting patient needs and delivering high-quality products.
  • Products are manufactured in Canada at EU-GMP and TGA-GMP certified facilities.

The big picture

Aurora's expansion into Australia and New Zealand underscores the company's strategic focus on international medical cannabis markets, which represent a key growth area given the limited penetration of cannabis-based therapies in these regions. This move reinforces Aurora's position as a leading global medical cannabis player, but also highlights the challenges of operating in regulated markets with varying patient access and product acceptance.

What we're watching

Market Penetration
The success of these launches hinges on Aurora’s ability to navigate Australia and New Zealand’s regulatory landscape and secure prescriber adoption, which will dictate the pace of revenue generation.
Proprietary Genetics
The reliance on proprietary genetics exposes Aurora to potential IP risks and the need for ongoing R&D investment to maintain a competitive advantage in a rapidly evolving market.
Regulatory Risk
Changes in regulations or increased scrutiny from Australian and New Zealand authorities could significantly impact Aurora’s ability to operate and expand its product offerings.

Aurora Cannabis Launches $100 Million ATM Offering to Fuel Expansion

Event summary

  • Aurora Cannabis has filed a prospectus supplement to establish a $100 million at-the-market (ATM) equity offering program.
  • Proceeds will be used for strategic and accretive purposes, specifically increased cultivation capacity and potential mergers & acquisitions (M&A).
  • Shares will be sold at the prevailing market price through NASDAQ or other U.S. marketplaces, with potential for privately negotiated transactions.
  • The ATM program is facilitated by TD Securities (USA) LLC and operates under National Instrument 44-102.

The big picture

Aurora’s decision to launch a $100 million ATM program indicates a continued need for capital to fund expansion, likely reflecting ongoing challenges in the competitive cannabis market. The program provides flexibility to raise funds as needed, but also introduces the risk of diluting existing shareholders. This move underscores the ongoing pressure on cannabis companies to demonstrate a clear path to profitability and sustainable growth.

What we're watching

Capital Allocation
The success of Aurora’s strategic initiatives will hinge on the effective deployment of these funds; M&A activity, in particular, carries integration risk and potential dilution.
Share Dilution
Frequent use of the ATM program could signal ongoing operational challenges and put downward pressure on the share price if not accompanied by strong performance.
Market Sentiment
Investor reaction to the ATM program will reflect broader sentiment towards the cannabis sector and Aurora’s ability to execute its growth plans in a competitive landscape.

Aurora Cannabis Launches $100 Million ATM Offering to Fuel Expansion

Event summary

  • Aurora Cannabis has filed a prospectus supplement to establish a $100 million at-the-market (ATM) offering program.
  • The program allows Aurora to issue and sell common shares from treasury at its discretion.
  • Proceeds will be used for strategic and accretive purposes, including cultivation capacity and potential M&A.
  • Sales will occur through at-the-market distributions on the NASDAQ or via privately negotiated transactions.
  • The ATM program is facilitated by TD Securities (USA) LLC.

The big picture

Aurora's ATM offering underscores the ongoing capital needs within the cannabis industry, particularly for companies seeking to expand cultivation and pursue acquisitions. While the program provides flexibility in raising funds, it also highlights the challenges in achieving sustainable profitability and reducing reliance on equity financing. The move signals a continued focus on growth, but investors should scrutinize the strategic rationale and potential dilution effects.

What we're watching

Capital Allocation
The success of Aurora's strategic initiatives will hinge on how effectively the raised capital is deployed, particularly given the history of capital misallocation in the cannabis sector.
Share Dilution
Continued reliance on ATM offerings signals ongoing funding needs and could lead to further share dilution, impacting existing shareholder value.
M&A Landscape
The stated intention to pursue M&A activity suggests Aurora may be seeking to consolidate its position, but the current market conditions could limit deal availability and pricing.

Aurora Cannabis Boosts European Digital Presence Amidst Market Evolution

Event summary

  • Aurora Cannabis launched four localized websites for key European medical cannabis markets: Germany, UK, Poland, and a central European hub.
  • The new websites emphasize Aurora's science-backed approach, manufacturing expertise, and brand strength, targeting healthcare professionals and partners.
  • Andreas Dotterweich, Senior Vice President, Aurora Europe, stated the investment demonstrates a long-term commitment to the region, Aurora’s fastest-growing market.
  • The websites are available in native languages and integrate with Aurora’s broader European communications strategy.

The big picture

Aurora's investment in localized digital infrastructure signals a strategic shift towards deeper engagement within key European medical markets, reflecting the increasing importance of these regions for global cannabis companies. This move is consistent with the broader trend of cannabis companies prioritizing medical markets with established regulatory frameworks over recreational ones. The success of this initiative will be a key indicator of Aurora’s ability to capitalize on the growing European medical cannabis market, which is expected to see significant growth in the coming years.

What we're watching

Market Adoption
The effectiveness of the localized websites will depend on their ability to resonate with European healthcare professionals and drive adoption of Aurora's products within regulated markets.
Regulatory Landscape
Continued expansion in Europe hinges on the evolving regulatory environment and Aurora’s ability to navigate varying national cannabis laws.
Competitive Response
Other medical cannabis companies will likely observe Aurora’s digital strategy and may respond with similar initiatives, potentially intensifying competition for market share.

Aurora Cannabis Schedules Q3 2026 Earnings Call Amidst Ongoing Market Volatility

Event summary

  • Aurora Cannabis will release its Q3 2026 financial results before market open on February 4, 2026.
  • An investor conference call is scheduled for February 4, 2026, at 8:00 AM Eastern Time.
  • Executive Chairman and CEO Miguel Martin and CFO Simona King will lead the call.
  • Aurora Cannabis trades on both the NASDAQ and TSX exchanges under the ticker symbol ACB.

The big picture

Aurora Cannabis, a significant player in the global medical cannabis market, faces ongoing headwinds from fluctuating consumer demand, increased competition, and evolving regulatory frameworks. The upcoming earnings call will provide insight into the company's efforts to adapt to these challenges and maintain its position within a rapidly maturing industry. The company's focus on both medical and adult-use markets across multiple continents highlights its ambition, but also exposes it to a wider range of geopolitical and economic risks.

What we're watching

Financial Performance
The Q3 results will be scrutinized for signs of stabilization or continued losses, given the challenging macroeconomic environment and ongoing regulatory uncertainties impacting the cannabis sector.
Executive Alignment
The continued presence of both Miguel Martin and Simona King suggests a degree of stability, but their commentary on strategic direction will be key to assessing future investment priorities.
Regulatory Landscape
How Aurora addresses potential new or increased tariffs on imports into the United States will be a critical indicator of its ability to navigate evolving regulatory hurdles.

Aurora Secures EU Plant Variety Rights for Key Cannabis Cultivars

Event summary

  • Aurora Cannabis has secured EU Community Plant Variety Rights for two proprietary cannabis varieties, SOT20R07-007 (Farm Gas™) and ACB21T044 (Sourdough™).
  • The varieties were bred in Canada through Aurora's breeding and phenotyping programs and are core products in Germany, Poland, UK, Canada, and Australia.
  • These rights grant Aurora exclusive commercial production and sales control within the EU's 27 member states.
  • The varieties are recognized for high potency, desirable aromas, consistency, and strong performance traits.

The big picture

Securing EU plant variety rights represents a strategic move for Aurora, reinforcing its position in the increasingly competitive global medical cannabis market. This development allows Aurora to control the propagation and sale of these specific cultivars, creating a barrier to entry for competitors and potentially commanding premium pricing. The move highlights the growing importance of intellectual property in the cannabis industry as companies seek to differentiate themselves and build sustainable competitive advantages in a consolidating market.

What we're watching

Commercialization
The speed at which Aurora can leverage these rights to expand sales and market share within the EU will be a key indicator of the program's value.
Competitive Response
How other cannabis producers react to Aurora's strengthened IP position and whether they attempt to develop competing varieties will shape the competitive landscape.
IP Enforcement
Aurora's ability to effectively enforce these rights against potential infringers will be crucial to protecting its investment and maintaining a competitive advantage.
CID: 3635